策略研究 证 券 研 究 报 告 【华创证券人工智能研究中心】 公募增配光通信、半导体设备、封测，减配芯片设 计、游戏、广告——多行业联合人工智能 2 月报 策略月报 2026 年 02 月 04 日 华创证券研究所 证券分析师：姚佩 邮箱：yaopei@hcyjs.com 执业编号：S0360522120004 证券分析师：耿琛 邮箱：gengchen@hcyjs.com 执业编号：S0360517100004 证券分析师：岳阳 电话：021-20572543 邮箱：zhangchenghang@hcyjs.com 执业编号：S0360519070003 邮箱：yueyang@hcyjs.com 执业编号：S0360521120002 证券分析师：吴鸣远 邮箱：wumingyuan@hcyjs.com 执业编号：S0360523040001 证券分析师：张程航 2026-01-26 《【华创策略】再通胀主线：五朵金花——策略周 聚焦》 2026-01-25 证监会审核华创证券投资咨询业务资格批文号：证监许可（2009）1210 号 证券分析师：范益民 电话：021-20572562 邮箱：fanyimin@ ...

Group 1 - The U.S. stock market experienced a collective decline, with the Dow Jones down 0.34%, Nasdaq down 1.43%, and S&P 500 down 0.83%, indicating a bearish sentiment in the tech sector as major companies like Broadcom, Microsoft, Nvidia, and Meta saw significant drops [3] - International oil prices rose, with WTI crude oil increasing by 3.12% to $64.08 per barrel and Brent crude oil up by 2.88% to $68.21 per barrel, reflecting a positive trend in the energy sector [4] - European stock indices closed slightly lower, with Germany's DAX down 0.07%, France's CAC40 down 0.02%, and the UK's FTSE 100 down 0.26%, indicating a cautious market environment in Europe [5] Group 2 - The Central Committee of the Communist Party of China released a document focusing on agricultural modernization and rural revitalization, emphasizing the need for technological innovation in agriculture and the development of key agricultural technologies [6] - The Ministry of Industry and Information Technology of China highlighted the importance of advancing in fields such as 6G, quantum technology, and bio-manufacturing, aiming for breakthroughs in these future industries [9] - The People's Bank of China announced an operation to conduct 800 billion yuan of reverse repos to maintain liquidity in the banking system, indicating a proactive monetary policy stance [10] Group 3 - The recent news regarding the "couple's online purchase of contaminated vegetables" led to legal actions against the individuals involved for extortion, showcasing the legal implications of consumer safety issues [11] - The incident at Lingyin Temple, where 380,000 reservations were made but many did not show up, prompted a review of the reservation system to improve attendance and manage visitor expectations [12] - Reports of potential increases in VAT rates for the gaming and financial sectors were dismissed by experts, reinforcing the stability of current tax policies in these industries [13] Group 4 - The announcement of a large-scale robot gala by Zhiyuan Robotics, set to be broadcasted globally, signifies a growing interest in integrating robotics with entertainment, potentially influencing the tech and entertainment sectors [21] - The response from Chaozhou Jewelry regarding quality concerns over their products, backed by authoritative testing, aims to maintain brand reputation and consumer trust [23] - Tencent's revival of the classic QQ Farm game is expected to enhance user engagement and interaction, reflecting a trend in leveraging nostalgia in gaming [24]

本文源自：金融界AI电报 礼来(LLY.N)股价下跌3%，此前其竞争对手诺和诺德(NVO.N)警告称，2026年销售额将大幅下滑。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...

Investment Rating - The report provides a positive outlook for CSPC Pharmaceutical Group, indicating a clear roadmap for internationalization and significant revenue growth expected from completed business development transactions by 2026 [5][6]. Core Insights - CSPC is projected to convert its completed business development transactions into recurring revenue by 2026, supported by major research milestones and successful overseas development progress [6]. - The company has secured approximately $10.2 billion in upfront and milestone payments from significant partnerships with AstraZeneca and Madrigal, which are expected to enhance profitability from 2025 to 2027 [5][6]. - Key products such as KN026 and SYS6010 are anticipated to drive domestic business recovery and accelerate growth post-2027 [7]. Summary by Sections Business Development and Revenue - CSPC's completed business development transactions are expected to yield around $9 billion in free cash flow from milestone payments by 2030, with AstraZeneca's recent $1.2 billion non-refundable upfront payment being a significant contributor [6]. - The company has established eight innovative R&D platforms, transitioning from a raw material producer to a complex generics and innovative drug enterprise, achieving a compound annual growth rate of 3.1% in profitability from 2019 to 2023 [10]. Market Position and Financials - As of February 2, 2026, CSPC's stock price was HKD 9.15, with a market capitalization of $13.54 billion [13]. - The company ranks among the top ten in the Chinese pharmaceutical industry by drug revenue, with a significant portion of its income derived from the Asian market [11]. Catalysts for Growth - Key catalysts include the progress of overseas R&D projects, particularly the core product EGFR ADC, and the clinical development plans of major partners like AstraZeneca [8]. - The anticipated launch of innovative drugs and the entry of early-stage products into clinical phases are expected to validate the company's R&D capabilities [8].

机构：国海证券 研究员：曹泽运/万鹏辉 投资要点: 持续达成研发合作，AI 制药能力不断被认可2021 年至今，公司已于多家国内外龙头药企达成研发合 作，其中2022 年跟赛诺菲达成最高12 亿美元+特许权使用费合作，2025 年跟礼来达成超1 亿美元+特许 权使用费合作，2026 年与施维雅达成多年期抗肿瘤药物研发合作，协议总金额高达8.88 亿美元。多家 国内外龙头药企陆续跟公司达成AI 平台研发合作，公司AI 平台研发能力不断被认可。 已有多款自研管线对外授权2023 年至今，公司已经完成3 笔对外自主研发管线的对外授权，分别为： 2023 年对EXELIXIS 授权USP1 靶点药物，总金额接近10 亿美元，其中首付款8000 万美元；2023 年对 Menarini 授权KAT6 小分子，总金额超过5 亿美元，其中首付款1200 万美元；2024 年继续对Menarini 授 权，总金额超过5.5亿美元，首付款2000 万美元，2025 年12 月授权太景PHD 抑制剂ISM4808 大中华区 开发、商业化和再许可权力，交易总额达数千万美元，以上均包含特许权使用费。2026 年1 月，对衡泰 生物授 ...

Investment Rating - The report indicates a strong growth outlook for the company, with projected net profit for 2025 expected to reach between 1.1 billion to 1.2 billion, representing a year-on-year growth of 79%-95% [1] Core Insights - The company's growth is primarily driven by a significant improvement in its domestic insulin business, which saw a revenue increase of 45.6% in the first three quarters of 2025, characterized by both volume and price increases [2][4] - The successful selection of all six products in the 2024 national procurement for insulin has led to a more than 30% increase in procurement volume compared to the previous round, providing a substantial boost in sales certainty [4] - The company's gross margin has stabilized above 73% over the past two years, indicating effective cost control and product structure optimization, allowing it to convert procurement pressure into market share and profit [4][6] Domestic Business Performance - The company has captured a 30% market share in the third-generation insulin procurement, positioning itself as the leading domestic player, second only to Novo Nordisk, amidst a trend of domestic products replacing imports [6] - The company’s products are now available in over 40,000 medical institutions, with rapid growth particularly in grassroots markets [6] International Expansion - International sales revenue reached 350 million in the first three quarters of 2025, marking a 45.5% year-on-year increase [7] - A significant 10-year technology transfer and supply agreement with Brazil, valued at no less than 3 billion, positions the company as the sole approved solution for Brazil's national public health system [7][9] - The company is transitioning from merely exporting products to a more sophisticated model of technology output, which includes local production technology transfer and talent development [9] Research and Development Focus - The company is heavily investing in R&D, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [10] - Key products in development include GZR4 (ultra-long-acting insulin), which is in Phase III clinical trials and aims to revolutionize patient treatment habits, and GZR18 (GLP-1 dual-week formulation), which has received FDA approval and shows promising weight loss results [11][12] - The company is also advancing GZR101 (premixed dual insulin) into Phase II clinical trials, aiming to provide more convenient treatment options [12] - The successful launch of either GZR4 or GZR18 could elevate the company from an "insulin expert" to a "comprehensive solution provider for metabolic diseases" [14]

2026 年 02 月 02 日 公司研究 评级：买入(首次覆盖) 研究所： 证券分析师： 曹泽运 S0350525110001 证券分析师： 万鹏辉 S0350524050003 caozy@ghzq.com.cn wanph@ghzq.com.cn [Table_Title] 与齐鲁制药达成合作，持续验证 AI 制药能力 ——英矽智能（03696）点评报告 最近一年走势 事件: 2026 年 1 月 27 日，英矽智能发布公告：公司与齐鲁制药签署战略合作 协议，双方将围绕心血管与代谢类疾病领域，利用英矽智能的 Pharma.AI 平台进行小分子抑制剂的研发。协议总金额超过 9.31 亿港元，包含开发 和销售里程碑付款，以及单位数的后续净销售额分成。 投资要点: | 相对恒生指数表现 | | 2026/01/30 | | | --- | --- | --- | --- | | 表现 | 1M | 3M 12M | | | 英矽智能 | 109.8% | - | - | | 恒生指数 | 5.9% | - | - | | 市场数据 | | 2026/01/30 | | | 当前价格（元） | | 62.90 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].